
Care continues to improve; however, drug-resistant pathogens and a lack of new agents to treat these infections remain a constant challenge.

Care continues to improve; however, drug-resistant pathogens and a lack of new agents to treat these infections remain a constant challenge.

Should clinicians be extra vigilant when deciding who receives antiviral therapy, or are the adverse effects few and infrequent?

Published: May 9th 2017 | Updated:

Published: August 8th 2017 | Updated: